ABSTRACT
The ketogenic diet (KD) has been shown to be effective in refractory epilepsy after long-term administration. However, its interference with short-term brain metabolism and its involvement in the early process leading to epilepsy remain poorly understood. This study aimed to assess the effect of a short-term ketogenic diet on cerebral glucose metabolic changes, before and after status epilepticus (SE) in rats, by using [18F]-FDG PET. Thirty-nine rats were subjected to a one-week KD (KD-rats, n = 24) or to a standard diet (SD-rats, n = 15) before the induction of a status epilepticus (SE) by lithium-pilocarpine administrations. Brain [18F]-FDG PET scans were performed before and 4 h after this induction. Morphological MRIs were acquired and used to spatially normalize the PET images which were then analyzed voxel-wisely using a statistical parametric-based method. Twenty-six rats were analyzed (KD-rats, n = 15; SD-rats, n = 11). The 7 days of the KD were associated with significant increases in the plasma ß-hydroxybutyrate level, but with an unchanged glycemia. The PET images, recorded after the KD and before SE induction, showed an increased metabolism within sites involved in the appetitive behaviors: hypothalamic areas and periaqueductal gray, whereas no area of decreased metabolism was observed. At the 4th hour following the SE induction, large metabolism increases were observed in the KD- and SD-rats in areas known to be involved in the epileptogenesis process late-i.e., the hippocampus, parahippocampic, thalamic and hypothalamic areas, the periaqueductal gray, and the limbic structures (and in the motor cortex for the KD-rats only). However, no statistically significant difference was observed when comparing SD and KD groups at the 4th hour following the SE induction. A one-week ketogenic diet does not prevent the status epilepticus (SE) and associated metabolic brain abnormalities in the lithium-pilocarpine rat model. Further explorations are needed to determine whether a significant prevention could be achieved by more prolonged ketogenic diets and by testing this diet in less severe experimental models, and moreover, to analyze the diet effects on the later and chronic stages leading to epileptogenesis.
Subject(s)
Diet, Ketogenic , Status Epilepticus , Rats , Animals , Pilocarpine/pharmacology , Lithium/pharmacology , Rats, Wistar , Fluorodeoxyglucose F18/pharmacology , Status Epilepticus/chemically induced , Status Epilepticus/diagnostic imaging , Brain/diagnostic imaging , Hippocampus , Disease Models, AnimalABSTRACT
Brain-restricted somatic variants in genes of the mechanistic target of rapamycin signalling pathway cause focal epilepsies associated with focal cortical dysplasia type II. We hypothesized that somatic variants could be identified from trace tissue adherent to explanted stereoelectroencephalography electrodes used in the presurgical epilepsy workup to localize the epileptogenic zone. We investigated three paediatric patients with drug-resistant focal epilepsy subjected to neurosurgery. In the resected brain tissue, we identified low-level mosaic somatic mutations in AKT3 and DEPDC5 genes. We collected stereoelectroencephalography depth electrodes in the context of a second presurgical evaluation and identified 4/33 mutation-positive electrodes that were either located in the epileptogenic zone or at the border of the dysplasia. We provide the proof-of-concept that somatic mutations with low levels of mosaicism can be detected from individual stereoelectroencephalography electrodes and support a link between the mutation load and the epileptic activity. Our findings emphasize future opportunities for integrating genetic testing from stereoelectroencephalography electrodes into the presurgical evaluation of refractory epilepsy patients with focal cortical dysplasia type II to improve the patients' diagnostic journey and guide towards precision medicine.
ABSTRACT
OBJECTIVE: Report of the contribution of invasive EEG (iEEG) and epileptogenicity mappings (EM) in a pediatric cohort of patients with epilepsy associated with focal polymicrogyria (PMG) and candidates for resective surgery. METHOD: Retrospective pediatric case series of patients presenting focal PMG-related refractory epilepsy undergoing an invasive exploration (iEEG) at Fondation Rothschild Hospital. We reviewed clinical data, structural MRI, and visual analysis of iEEG recordings. Moreover, time-frequency analysis of SEEG signals with a neuroimaging approach (epileptogenicity maps) was used to support visual analysis. RESULTS: Between 2012 and 2019, eight patients were selected. Five patients were explored with stereoelectroencephalography (SEEG) only, one patient with subdural exploration (SDE) only and two patients first underwent SEEG and then SDE. The mean age at seizure onset was 40.3 months (range 3-120), and the mean age for the iEEG 10.8 years (range 7-15). The epileptogenic zone (EZ) appeared concordant to the PMG lesion in only one case, was larger in three cases, smaller in two cases and different in one case. Four cases were selected for tailored resective surgery and one for total callosotomy. Two patients remained seizure-free at their last follow-up (mean 32.6 months, range 7-98). Epileptogenicity mapping (EM) refined the qualitative analysis, showing in four patients an EZ larger than visually defined. CONCLUSION: This study is the first pediatric study to analyze the value of iEEG and EM as well as operability in focal PMG-related refractory epilepsy. The results illustrate the complexity of this pathology with variable concordance between the EZ and the lesion and mixed response to surgery.
Subject(s)
Drug Resistant Epilepsy , Polymicrogyria , Adolescent , Child , Child, Preschool , Drug Resistant Epilepsy/surgery , Electroencephalography , Humans , Infant , Polymicrogyria/complications , Polymicrogyria/diagnostic imaging , Polymicrogyria/surgery , Retrospective Studies , Stereotaxic TechniquesABSTRACT
For a ketogenic diet to be effective, strict control of carbohydrate intake is paramount. Factors such as medications may upset this delicate balance. The aim of this commentary is to provide physicians who are treating patients with a ketogenic diet, with a step-by-step guide. A list of unsuitable excipients was established. A flowchart with the title "Can this drug be prescribed to a patient following a ketogenic diet?" was then drafted. The first step is to determine the international nonproprietary name, dosage, form and composition. The amount of unsuitable excipients is calculated. Suitable alternatives may be discussed with the pharmacist. As a last resort, the ketogenic diet itself may need to be adapted. The answers provided are included in a database. Determining the amount of unsuitable excipients is a complex task requiring pharmaceutical expertise. Our flowchart can be used in order to provide a clear pathway for answering such questions.
Subject(s)
Carbohydrates/chemistry , Diet, Ketogenic/methods , Excipients/chemistry , Prescription Drugs/chemistry , Carbohydrates/adverse effects , Excipients/adverse effects , Humans , Prescription Drugs/adverse effectsABSTRACT
PURPOSE: The Statistical Parametric Mapping (SPM) software is frequently used for the quantitative analysis of patients' brain images obtained from 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography ([18F]FDG PET). However, its adaptation to small animals is difficult, particularly for the initial step of spatial normalization which requires a specific brain anatomical template. This study was aimed at determining whether SPM analysis can be applied to rat, and more specifically to the lithium-pilocarpine model of epilepsy, by using an adaptive template. This template developed for PET clinical imaging is constructed from a block matching algorithm. PROCEDURES: SPM analysis of brain [18F]FDG PET images from Sprague-Dawley rats was used with the block matching (BM) adaptive template for the detection of brain abnormalities (1) artificially inserted within the initially normal brain images of 10 rats (50 % decrease in signal intensity within 40 spheres of 0.5 to 1.0 mm in diameter) and (2) occurring at 4 h (n = 16), 48 h (n = 15), and 8 days (n = 13) after lithium-pilocarpine treatment. RESULTS: Concordant positive clusters were documented for all inserted abnormalities, whereas no aberrant clusters were documented in remote brain areas. Positive clusters were also detected on sites known to be involved in the epileptogenesis process of the lithium-pilocarpine model (piriform and entorhinal cortex, hippocampus), with the expected time-specific changes involving an early hypermetabolism followed by a severe hypometabolism and a subsequent partial recovery. CONCLUSION: A quantitative SPM analysis of brain [18F]FDG PET images may be applied to the monitoring of rat brain function when using an adaptive BM template.
Subject(s)
Brain/diagnostic imaging , Fluorodeoxyglucose F18/chemistry , Positron-Emission Tomography , Statistics as Topic , Animals , Imaging, Three-Dimensional , Male , Rats, Sprague-DawleyABSTRACT
BACKGROUND: Metabolic and inflammatory conditions may lead to neurological disorders. Neuromyelitis optica spectrum disorders (NMOSDs) refer to a rare group of demyelinating diseases of the central nervous system which essentially involve the optic nerves and spinal cord. METHODS: We report a case of biotinidase deficiency (BD) initially misdiagnosed as NMOSD in a pediatric patient. RESULTS: An 8-year-old girl was initially diagnosed with NMOSD on the basis of optic neuritis (ON) associated with three episodes of longitudinally extensive transverse myelitis (LETM). Intravenous high-dose corticosteroids were effective during the first two episodes of LETM. The third acute episode which resulted in tetraplegia, respiratory distress, and blindness was refractory to corticosteroids, plasmapheresis, and rituximab. The unusual clinical course and persistent high levels of plasma and cerebrospinal fluid (CSF) lactate led to additional metabolic investigations being performed. Acylcarnitine profile revealed increased C5-OH acylcarnitine suggestive of BD. Diagnosis was confirmed by direct assessment of plasma enzyme activity (quantified as 5% of the control value). Genetic analysis revealed two mutations, c.643C>T (p.L215F) and c.1612C>T (p.R538C), in the BTD gene (3p25). Dramatic clinical improvement occurred after long-term oral biotin treatment. CONCLUSION: BD is a treatable condition that may closely mimic the neurological findings of LETM and NMOSD.
Subject(s)
Biotinidase Deficiency/diagnosis , Neuromyelitis Optica/diagnosis , Adrenal Cortex Hormones/therapeutic use , Aquaporin 4/metabolism , Autoantibodies/blood , Biotinidase Deficiency/enzymology , Biotinidase Deficiency/genetics , Child , Diagnosis, Differential , Female , Humans , Spinal Cord/metabolismABSTRACT
Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia. Here, we report the first identification of a gene involved in Lichtenstein-Knorr syndrome. By using a combination of homozygosity mapping and whole-exome sequencing, we identified the homozygous p.Gly305Arg missense mutation in SLC9A1 that segregates with the disease in a large consanguineous family. Mutant glycine 305 is a highly conserved amino acid present in the eighth transmembrane segment of all metazoan orthologues of NHE1, the Na(+)/H(+) exchanger 1, encoded by SLC9A1. We demonstrate that the p.Gly305Arg mutation causes the near complete de-glycosylation, mis-targeting and loss of proton pumping activity of NHE1. The comparison of our family with the phenotypes of spontaneous and knockout Slc9a1 murine models demonstrates that the association between ataxia and hearing loss is caused by complete or near complete loss of function of NHE1 and altered regulation of pHi in the central nervous system.
Subject(s)
Cation Transport Proteins/genetics , Cerebellar Ataxia/genetics , Deafness/genetics , Fibrous Dysplasia of Bone/genetics , Immunologic Deficiency Syndromes/genetics , Mutation, Missense , Neutropenia/genetics , Sodium-Hydrogen Exchangers/genetics , Animals , Cation Transport Proteins/metabolism , Cerebellar Ataxia/metabolism , Deafness/metabolism , Facies , Female , Fibrous Dysplasia of Bone/metabolism , Humans , Immunologic Deficiency Syndromes/metabolism , Male , Mice , Mice, Knockout , Neutropenia/metabolism , Sodium-Hydrogen Exchanger 1 , Sodium-Hydrogen Exchangers/metabolismABSTRACT
Epileptic encephalopathy (EE) refers to a clinically and genetically heterogeneous group of severe disorders characterized by seizures, abnormal interictal electro-encephalogram, psychomotor delay, and/or cognitive deterioration. We ascertained two multiplex families (including one consanguineous family) consistent with an autosomal-recessive inheritance pattern of EE. All seven affected individuals developed subclinical seizures as early as the first day of life, severe epileptic disease, and profound developmental delay with no facial dysmorphism. Given the similarity in clinical presentation in the two families, we hypothesized that the observed phenotype was due to mutations in the same gene, and we performed exome sequencing in three affected individuals. Analysis of rare variants in genes consistent with an autosomal-recessive mode of inheritance led to identification of mutations in SLC13A5, which encodes the cytoplasmic sodium-dependent citrate carrier, notably expressed in neurons. Disease association was confirmed by cosegregation analysis in additional family members. Screening of 68 additional unrelated individuals with early-onset epileptic encephalopathy for SLC13A5 mutations led to identification of one additional subject with compound heterozygous mutations of SLC13A5 and a similar clinical presentation as the index subjects. Mutations affected key residues for sodium binding, which is critical for citrate transport. These findings underline the value of careful clinical characterization for genetic investigations in highly heterogeneous conditions such as EE and further highlight the role of citrate metabolism in epilepsy.
Subject(s)
Brain Diseases/genetics , Genes, Recessive , Mutation , Seizures/genetics , Symporters/genetics , Brain Diseases/complications , Female , Humans , Male , Pedigree , Seizures/etiologyABSTRACT
Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels contribute to cationic Ih current in neurons and regulate the excitability of neuronal networks. Studies in rat models have shown that the Hcn1 gene has a key role in epilepsy, but clinical evidence implicating HCN1 mutations in human epilepsy is lacking. We carried out exome sequencing for parent-offspring trios with fever-sensitive, intractable epileptic encephalopathy, leading to the discovery of two de novo missense HCN1 mutations. Screening of follow-up cohorts comprising 157 cases in total identified 4 additional amino acid substitutions. Patch-clamp recordings of Ih currents in cells expressing wild-type or mutant human HCN1 channels showed that the mutations had striking but divergent effects on homomeric channels. Individuals with mutations had clinical features resembling those of Dravet syndrome with progression toward atypical absences, intellectual disability and autistic traits. These findings provide clear evidence that de novo HCN1 point mutations cause a recognizable early-onset epileptic encephalopathy in humans.
Subject(s)
Aicardi Syndrome/genetics , Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels/genetics , Point Mutation , Potassium Channels/genetics , Spasms, Infantile/genetics , Amino Acid Sequence , Animals , CHO Cells , Child, Preschool , Cohort Studies , Cricetinae , Cricetulus , DNA Mutational Analysis , Female , Humans , Infant , Male , Molecular Sequence Data , Mutation, Missense , Patch-Clamp Techniques , Pedigree , Sequence Analysis, DNA , Sequence Homology, Amino AcidABSTRACT
Infantile spasms are seizures manifesting within a spectrum of epileptic encephalopathies of infancy that often lead to cognitive impairment. Their current therapies, including adrenocorticotropic hormone (ACTH), high dose steroids, or vigabatrin, are not always effective and may be associated with serious side effects. Overactivation of the TORC1 complex of the mTOR pathway is implicated in the pathogenesis of certain genetic and acquired disorders that are linked with infantile spasms, like tuberous sclerosis. Here, we tested the therapeutic potential of rapamycin, a TORC1 inhibitor, as a potential treatment for infantile spasms in the multiple-hit rat model of ACTH-refractory symptomatic infantile spasms, which is not linked to tuberous sclerosis. Rapamycin or vehicle was given after spasms appeared. Their effects on spasms, other seizures, performance in Barnes maze, and expression of the phosphorylated S6 ribosomal protein (pS6: a TORC1 target) in the cortex, using immunofluorescence, were compared. Rapamycin suppressed spasms dose-dependently and improved visuospatial learning, although it did not reduce the frequency of other emerging seizures. High-dose pulse rapamycin effected acute and sustained suppression of spasms and improved cognitive outcome, without significant side effects. Therapeutically effective rapamycin doses normalized the pS6 expression, which was increased in perilesional cortical regions of pups with spasms. These findings support that pathological overactivation of TORC1 may be implicated in the pathogenesis of infantile spasms, including those that are not linked to tuberous sclerosis. Furthermore, a high-dose, pulse rapamycin treatment is a promising, well tolerated and disease-modifying new therapy for infantile spasms, including those refractory to ACTH.
Subject(s)
Cognition Disorders/drug therapy , Sirolimus/pharmacology , Spasms, Infantile/drug therapy , Animals , Animals, Newborn , Cognition Disorders/etiology , Cognition Disorders/prevention & control , Disease Models, Animal , Drug Administration Schedule , Humans , Infant, Newborn , Male , Rats , Rats, Sprague-Dawley , Sirolimus/therapeutic use , Spasms, Infantile/complications , Spasms, Infantile/prevention & control , Transcription Factors/antagonists & inhibitors , Transcription Factors/metabolism , Transcription Factors/physiologyABSTRACT
PURPOSE: Lafora disease (LD) is an autosomal recessive form of progressive myoclonus epilepsy with onset in childhood or adolescence and with fatal outcome caused by mutations in two genes: EPM2A and NHLRC1. The aim of this study was to characterize the mutation spectrum in a cohort of unrelated patients with presumed LD. METHODS: Sequencing of the two genes and search for large rearrangements was performed in 46 unrelated patients with suspected LD, 33 originating from France and the others from different countries. Patients were classified into two groups according to the clinical presentation. RESULTS: Mutations of various types were found in EPM2A in 10 patients and in NHLRC1 in 4 patients. Mutations were found in 14 (93%) of 15 patients with classical clinical and electroencephalography (EEG) presentation of LD and in no patients with an atypical presentation. Ten mutations were novel, including the first substitution reported in a donor splice site of EPM2A, leading to the deletion of exon 2 at the RNA level. Four large deletions, including two deletions of exon 2 with different sizes and breakpoints, were found in EPM2A, corresponding to 20% of the alleles of this gene. DISCUSSION: We described several novel mutations of EPM2A and NHLRC1 and brought additional data to the genetic epidemiology of LD. This study emphasized the high mutation rate in patients with classical LD as well as the high negativity rate of skin biopsy.
Subject(s)
Carrier Proteins/genetics , Lafora Disease/genetics , Mutation/genetics , Protein Tyrosine Phosphatases, Non-Receptor/genetics , Adolescent , Adult , Biopsy , Exons/genetics , Female , Genetic Markers/genetics , Humans , Lafora Disease/diagnosis , Lafora Disease/pathology , Male , Microsatellite Repeats/genetics , Pedigree , Skin/pathology , Ubiquitin-Protein LigasesABSTRACT
PURPOSE: Although the number of antiepileptic drugs (AEDs) is increasing, none displays neuroprotective or antiepileptogenic properties that could prevent status epilepticus (SE)-induced drug-resistant epilepsy. Ketogenic diet (KD) and calorie restriction (CR) are proposed as alternative treatments in epilepsy. Our goal was to assess the neuroprotective or antiepileptogenic effect of these diets in a well-characterized model of mesial temporal lobe epilepsy following initial SE induced by lithium-pilocarpine in adult rats. METHODS: Seventy-five P50 male Wistar rats were fed a specific diet: normocalorie carbohydrate (NC), hypocalorie carbohydrate (HC), normocalorie ketogenic (NK), or hypocalorie ketogenic (HK). Rats were subjected to lithium-pilocarpine SE, except six NC to constitute a control group for histology (C). Four rats per group were implanted with epidural electrodes to record electroencephalography (EEG) during SE and the next six following days. From the seventh day, the animals were video-recorded 10 h daily to determine latency to epilepsy onset. Neuronal loss in hippocampus and parahippocampal cortices was analyzed 1 month after the first spontaneous seizure. RESULTS: After lithium-pilocarpine injection, neither KD nor CR modified SE features or latency to epilepsy. In hippocampal layers, KD or CR exhibited a neuroprotective potential without cooperative effect. Parahippocampal cortices were not protected by the diets. CONCLUSION: The antiepileptic effect of KD and/or CR is overwhelmed by lithium-pilocarpine injection. The isolated protection of hippocampal layers induced by KD or CR or their association failed to modify the course of epileptogenesis.
Subject(s)
Anticonvulsants/pharmacology , Caloric Restriction/methods , Diet, Ketogenic/methods , Epilepsy, Temporal Lobe/prevention & control , Hippocampus/drug effects , Neuroprotective Agents/pharmacology , Animals , Cerebral Cortex/drug effects , Dietary Carbohydrates/administration & dosage , Disease Models, Animal , Drug Resistance , Electroencephalography/drug effects , Electroencephalography/statistics & numerical data , Epilepsy, Temporal Lobe/chemically induced , Epilepsy, Temporal Lobe/drug therapy , Humans , Lithium Chloride , Male , Pilocarpine , Rats , Rats, Wistar , Status Epilepticus/chemically inducedABSTRACT
Infantile spasms are the classical seizure type of West syndrome. Infantile spasms often herald a dismal prognosis, due to the high probability to evolve into intractable forms of epilepsies with significant cognitive deficits, especially if not adequately treated. The current therapies-high doses of adrenocorticotropic hormone, steroids, or the gamma-aminobutyric acid (GABA) transaminase inhibitor vigabatrin--are often toxic and may not always be effective. The need to identify new therapies for spasms has led to the generation of a number of rodent models of infantile spasms. These include acute and chronic models of infantile spasms, with cryptogenic or symptomatic origin, many of which are based on specific etiologies. In this review, we summarize the clinical experience with treating infantile spasms and the main features of the new animal models of infantile spasms and discuss their utility in the preclinical development of new therapies for infantile spasms.
Subject(s)
Spasms, Infantile/etiology , Adrenocorticotropic Hormone/therapeutic use , Animals , Anticonvulsants/therapeutic use , Disease Models, Animal , Humans , Infant , Mice , Rats , Receptors, GABA/drug effects , Sirolimus/therapeutic use , Spasms, Infantile/drug therapy , Vigabatrin/therapeutic useABSTRACT
Establishing an early diagnosis of Lafora disease (LD) is often challenging. We describe two cases of LD presenting as myoclonus and tonic-clonic seizures, initially suggesting idiopathic generalized epilepsy. The subsequent course of the disease was characterized by drug-resistant myoclonic epilepsy, cognitive decline, and visual symptoms, which oriented the diagnosis toward progressive myoclonic epilepsy and, more specifically, LD. Early in the evolution in the first case, and before histopathologic and genetic confirmation of LD in both cases, [18]Fluorodeoxyglucose positron emission tomography (FDG-PET) revealed posterior hypometabolism, consistent with the well-known posterior impairment in this disease. This suggests that FDG-PET could help to differentiate LD in early stages from other progressive myoclonic epilepsies, but confirmation is required by a longitudinal study of FDG-PET in progressive myoclonic epilepsy.
Subject(s)
Blood Glucose/metabolism , Electroencephalography , Energy Metabolism/physiology , Epilepsy, Tonic-Clonic/diagnostic imaging , Image Processing, Computer-Assisted , Lafora Disease/diagnostic imaging , Occipital Lobe/diagnostic imaging , Positron-Emission Tomography , Signal Processing, Computer-Assisted , Tomography, X-Ray Computed , Adolescent , Biopsy , Brain/diagnostic imaging , Carrier Proteins/genetics , Cerebral Cortex/diagnostic imaging , Child, Preschool , DNA Mutational Analysis , Diagnosis, Differential , Disease Progression , Dominance, Cerebral/physiology , Epilepsy, Tonic-Clonic/pathology , Female , Fluorodeoxyglucose F18 , Genetic Carrier Screening , Humans , Lafora Disease/pathology , Skin/pathology , Ubiquitin-Protein LigasesABSTRACT
Idiopathic partial reading epilepsy (RE) is a rare syndrome. We report the clinical and electroencephalographic characteristics of two right-handed patients with the following: reading-induced independent bilateral temporal lobe seizures, accompanied by alexia in left (dominant) sided seizures recorded on video-EEG (electroencephalography); subclinical activation over left posterior temporal and occipital electrodes during reading; no spontaneous seizure and no other trigger than reading; onset in adolescence; and history of varying resistance to treatment. Bilateral independent temporal lobe reflex seizures are part of the clinical spectrum of RE. It may result from hyperexcitability of bilateral cortical networks involved in the early steps of the reading process.
Subject(s)
Dyslexia/diagnosis , Epilepsy, Reflex/diagnosis , Epilepsy, Temporal Lobe/diagnosis , Functional Laterality/physiology , Adolescent , Adult , Age of Onset , Cerebral Cortex/physiopathology , Dyslexia/epidemiology , Electroencephalography/statistics & numerical data , Epilepsies, Partial/diagnosis , Epilepsies, Partial/epidemiology , Epilepsy, Reflex/epidemiology , Epilepsy, Reflex/physiopathology , Epilepsy, Temporal Lobe/epidemiology , Humans , Male , Reading , Syndrome , Video RecordingABSTRACT
Infantile spasms are characterized by age-specific expression of epileptic spasms and hypsarrhythmia and often result in significant cognitive impairment. Other epilepsies or autism often ensue especially in symptomatic IS (SIS). Cortical or subcortical damage, including white matter, have been implicated in the pathogenesis of SIS. To generate a model of SIS, we recreated this pathology by injecting rats with lipopolysaccharide and doxorubicin intracerebrally at postnatal day (P) 3 and with p-chlorophenylalanine intraperitoneally at P5. Spasms occurred between P4 and 13 and were associated with ictal EEG correlates, interictal EEG abnormalities and neurodevelopmental decline. After P9 other seizures, deficits in learning and memory, and autistic-like behaviors (indifference to other rats, increased grooming) were observed. Adrenocorticotropic hormone (ACTH) did not affect spasms. Vigabatrin transiently suppressed spasms at P5. This new model of SIS will be useful to study the neurobiology and treatment of SIS, including those that are refractory to ACTH.
Subject(s)
Brain Damage, Chronic/chemically induced , Brain Damage, Chronic/physiopathology , Brain/drug effects , Brain/physiopathology , Spasms, Infantile/chemically induced , Spasms, Infantile/physiopathology , Adrenocorticotropic Hormone/pharmacology , Animals , Animals, Newborn , Antibiotics, Antineoplastic/toxicity , Anticonvulsants/pharmacology , Autistic Disorder/chemically induced , Autistic Disorder/pathology , Autistic Disorder/physiopathology , Brain/metabolism , Brain Damage, Chronic/pathology , Cognition Disorders/chemically induced , Cognition Disorders/pathology , Cognition Disorders/physiopathology , Disease Models, Animal , Doxorubicin/toxicity , Drug Resistance/physiology , Electroencephalography/drug effects , Evoked Potentials/drug effects , Evoked Potentials/physiology , Fenclonine/toxicity , Humans , Infant, Newborn , Inflammation Mediators/toxicity , Lipopolysaccharides/toxicity , Male , Neurodegenerative Diseases/chemically induced , Neurodegenerative Diseases/pathology , Neurodegenerative Diseases/physiopathology , Rats , Serotonin Antagonists/toxicity , Spasms, Infantile/complications , Vigabatrin/pharmacologyABSTRACT
In the present study, we explored the consequences of epilepsy on the neurobehavioral development of the offspring in a rat model of spontaneous epilepsy, the lithium-pilocarpine model of temporal lobe epilepsy not dependent on genetic factors and in animals not receiving any antiepileptic treatment. Status epilepticus was induced by lithium-pilocarpine in female rats. After the occurrence of spontaneous seizures the rats were mated and the neurobehavioral development of the offspring was explored. Rat pups were cross-fostered early after birth. We hence obtained pups born from or raised by epileptic or non-epileptic dams. On the dams, we performed a follow-up of maternal care during pregnancy. On the pups, we performed a follow-up of classical parameters of development such as body weight and eyelid opening, and subjected the pups to various tests representative of neurobehavioral maturation extending from postnatal day 4 (PD4) to PD30 (righting reflex, suspension time, negative geotaxis, open field, locomotor coordination and eight arm maze). Altogether our data show that rat pups born from or raised by epileptic dams develop as well as control pups raised by control dams. Intriguingly, pups born from lithium-pilocarpine exposed dams and raised by control mothers tend to have better scores than the two other groups in all tests. This indicates that the exposure to seizures during pregnancy is not harmful for the development of the fetus.
Subject(s)
Antipsychotic Agents/toxicity , Behavior, Animal/drug effects , Lithium/toxicity , Muscarinic Agonists/toxicity , Pilocarpine/toxicity , Prenatal Exposure Delayed Effects , Age Factors , Animals , Animals, Newborn , Body Weight/drug effects , Chi-Square Distribution , Disease Models, Animal , Epilepsy/chemically induced , Epilepsy/physiopathology , Exploratory Behavior/drug effects , Eyelids/drug effects , Female , Locomotion/drug effects , Male , Maternal Exposure , Maze Learning/drug effects , Pregnancy , Psychomotor Performance/drug effects , Random Allocation , Rats , Rats, Sprague-Dawley , Reflex/drug effects , Social BehaviorABSTRACT
PURPOSE: Thresholds to pentylenetetrazol (PTZ) seizures were usually based only on clinical symptoms. Our purpose was to use electroclinical patterns to assess the efficacy of a ketogenic and/or calorie-restricted diet on PTZ-induced seizures. METHODS: Forty 50-day-old rats were divided in four weight-matched groups and fed controlled diets: normocalorie carbohydrate (NC), hypocalorie carbohydrate (HC), normocalorie ketogenic (NK), and hypocalorie ketogenic (HK). After 21 days, blood glucose and beta-hydroxybutyrate levels were determined and seizures were induced by continuous infusion of PTZ. The clinical and EEG thresholds to each seizure pattern were compared between the different groups. RESULTS: The electroclinical course of PTZ-induced seizures was similar in all groups. The HK group exhibited higher thresholds than the other ones for most clinical features: absence (p = 0.003), first overt myoclonia (p = 0.028), clonic seizure (p = 0.006), and for EEG features: first spike (p = 0.036), first spike-and-wave discharge (p = 0.014), subcontinuous spike-and-wave discharges (p = 0.005). NK, HC, and NC groups were not significantly different from each other. Blood glucose and beta-hydroxybutyrate levels were not correlated with electroclinical seizure thresholds. After the clonic seizure, despite stopping PTZ infusion, a tonic seizure occurred in some animals, without significant difference regarding the diet. CONCLUSION: This approach permitted a precise study of the electroclinical course of PTZ-induced seizures. In addition to the usually studied first overt myoclonia, we clearly demonstrated the efficiency of a calorie restricted KD in elevating thresholds to most electroclinical seizure patterns. We confirmed the lack of efficiency of the KD to reduce seizure severity once the seizure has started.
Subject(s)
Caloric Restriction/methods , Electroencephalography/statistics & numerical data , Epilepsy/chemically induced , Epilepsy/physiopathology , Ketosis/metabolism , Pentylenetetrazole , 3-Hydroxybutyric Acid/blood , Animals , Blood Glucose/analysis , Body Weight/physiology , Cerebral Cortex/drug effects , Cerebral Cortex/physiopathology , Dietary Carbohydrates/administration & dosage , Dietary Carbohydrates/metabolism , Dietary Fats/administration & dosage , Dietary Fats/metabolism , Disease Models, Animal , Energy Intake , Epilepsy/diet therapy , Ketosis/etiology , Male , Rats , Rats, WistarABSTRACT
The lithium-pilocarpine (Li-Pilo) model of epilepsy reproduces some pathophysiological, temporal, and developmental features of human temporal lobe epilepsy. In this model, rates of cerebral glucose utilization measured by the [(14)C]2-deoxyglucose technique increased during the initial status epilepticus (SE) and decreased during the latent or chronic periods. To correlate these metabolic changes with the activities of the enzymes of the glycolytic and tricarboxylic acid cycle pathways, we measured by histoenzymology the regional activity of two key enzymes of glucose metabolism, lactate dehydrogenase (LDH) for the anaerobic pathway and cytochrome oxidase (CO) for the aerobic pathway coupled to oxidative phosphorylation, at various times after SE induced by Li-Pilo in 10- (P10), 21-d-old (P21) and adult rats for CO and in adult rats only for LDH. CO activity was slightly affected in P10 and P21 rats only at 4 and 24 h and normalized by 14 d after SE. In adult rats, CO activity decreased at 4 and 24 h in damaged areas, like entorhinal cortex, hippocampal CA3 area, amygdala, and thalamus. At 14 d after SE, CO activity was decreased only in entorhinal cortex and increased in brainstem regions involved in the remote control of seizures. In adult rats, LDH activity decreased at 24 h and 14 d after SE in sensorimotor and entorhinal cortex. These data show that the enzymatic equipment underlying the metabolism of glucose is not severely affected by Li-Pilo SE and confirm our previous observations concerning the relative metabolic hyperactivity of brain regions involved in the seizure circuit despite marked neuronal loss.